Achieve Life Sciences, Inc.
QUIT Nasdaq
SEC CIK 949858
Follow Achieve Life Sciences
Weekly email: filings, results
Net income
−$12.1M
+16.1% vs same quarter last year
EPS, diluted
−$0.11
+60.7% vs same quarter last year
Operating cash flow
−$8.4M
+26.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$54.6M |
| FY24 | −$39.8M |
| FY23 | −$29.8M |
| FY22 | −$42.4M |
| FY21 | −$33.2M |
| FY20 | −$14.7M |
| FY19 | −$16.4M |
| FY18 | −$12.7M |
| FY17 | −$10.6M |
| FY16 | −$1.2M |
| FY15 | −$828K |
| FY14 | −$26.2M |
| FY13 | −$31.8M |
| FY12 | −$21.1M |
| FY11 | −$14.7M |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$49.5M |
| FY24 | - |
| FY23 | −$24.5M |
| FY22 | - |
| FY21 | - |
| FY20 | −$13.5M |
| FY19 | −$15.3M |
| FY18 | −$10.7M |
| FY17 | - |
| FY16 | −$248K |
| FY15 | −$721K |
| FY14 | −$17.4M |
| FY13 | −$36.2M |
| FY12 | −$43.8M |
| FY11 | −$20.3M |